AN OPEN-LABEL MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-2100 IN PATIENTS WITH RECURRENT ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCRCC)

Brief description of study

This is a study seeing if a new cellular medicine called AB-2100, a logic-gated CAR T cell targeting PSMA and Ca-IX, is effective for adult patients with a specific type of advanced kidney cancer called clear-cell renal cell carcinoma (ccRCC). The study team wants to the safety and anti-cancer effectiveness of this medicine. Patients will try different doses of AB-2100 in the first part of the study, and once they figure out the right amount that has tolerable side effects, more patients will receive the treatment in the second part. The study is split into different steps for each patient, like checking if they're a good fit for the study, getting cell samples from the patient, preparing the body for treatment, receiving the medicine, and then seeing how things go afterward concerning treatment.


Clinical Study Identifier: s23-01596
ClinicalTrials.gov Identifier: NCT06245915
Principal Investigator: Minas Platon Economides.
Other Investigators: Mohammad I Abu Zaid, Victor Ricardo Adorno Febles, Rafael C Singson, Amanda Marie Ferris, Rena Kandinova, Jamie Robin Nemrow, Jingmei Hsu, Scot Niglio, Jamie M Pavlonnis, Kelsey Stocker, Laura P. Diaz, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.